ファーマコゲノミクスの世界市場レポート 2025

ファーマコゲノミクス市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.5％で148億1,000万米ドルに成長します。予測期間の成長は、高齢化人口の増加、慢性疾患の増加、人口増加、がん治療需要の増加に起因すると考えられます。予測期間中の主な動向としては、先進治療のより詳細な解析のためのゲノム編集ソリューションの発売、遺伝子データを解析するためのゲノミクスにおける人工知能（AI）の統合への注力、メタゲノミクスの進展、市場プレイヤー間の戦略的パートナーシップや提携、遺伝子発現や機能への影響を研究するための3次元（3D）ゲノミクスのイントロダクション、感染症や遺伝子編集に焦点を当てた新製品のイノベーション、情報に基づいた意思決定のための向精神薬ファーマコゲノミクス検査の開発などが挙げられます。

精密医療に対する需要の高まりがファーマコゲノミクス市場の拡大を後押ししています。プレシジョン・メディシンは、特定の患者サブセットに合わせた個別化治療に焦点を当てたヘルスケアモデルであり、特に腫瘍学などの先進領域で支持を集めています。その応用範囲は末期疾患にとどまらず、希少疾患や遺伝的疾患にも及んでいます。プレシジョン医療は、遺伝情報と環境情報を統合し、特定の疾患や反応に合わせた治療を行うことを目的としています。2022年3月の主要企業の記事によれば、今後5年間で精密医療への投資は1/3に増加するといいます。3,000万人の2型糖尿病患者が診断され治療を受けているアメリカでは、精密医療は個別化された治療を提供し、現在の診療を再構築しています。精密医療に対する需要の高まりは、ファーマコゲノミクス市場を推進する重要な要因です。

ファーマコゲノミクス市場は、慢性疾患の有病率の増加により成長が見込まれています。長期にわたって持続する慢性疾患は、世界の健康上の大きな課題となっています。ファーマコゲノミクスは、薬物反応に影響を及ぼす個々の遺伝的変異を考慮し、個別化された治療アプローチを提供します。世界保健機関（WHO）の2023年9月の報告書によると、非感染性疾患（NCDs）または慢性疾患は、世界の年間死亡者数4,100万人の74％を占めています。心血管疾患、がん、慢性呼吸器疾患、糖尿病がこの負担に大きく寄与しています。慢性疾患の増加動向は、ファーマコゲノミクス市場を推進する大きな要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ファーマコゲノミクス PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のファーマコゲノミクス市場：成長率分析
• 世界のファーマコゲノミクス市場の実績：規模と成長, 2019-2024
• 世界のファーマコゲノミクス市場の予測：規模と成長, 2024-2029, 2034F
• 世界ファーマコゲノミクス総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のファーマコゲノミクス市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 次世代シーケンシング
• ポリメラーゼ連鎖反応
• ゲル電気泳動
• 質量分析
• マイクロアレイ
• その他のテクノロジー
• 世界のファーマコゲノミクス市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 神経疾患
• 感染症
• 腫瘍学
• 心血管疾患
• 疼痛管理
• その他の用途
• 世界のファーマコゲノミクス市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 調査機関
• 学術機関
• その他のエンドユーザー
• 世界のファーマコゲノミクス市場、次世代シーケンシング（NGS）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全ゲノム配列解析
• ターゲットシーケンシング
• エクソームシークエンシング
• 世界のファーマコゲノミクス市場、ポリメラーゼ連鎖反応（PCR）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 定量PCR（qPCR）
• 逆転写PCR（RT-PCR）
• デジタルPCR
• 世界のファーマコゲノミクス市場、ゲル電気泳動のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アガロースゲル電気泳動
• ポリアクリルアミドゲル電気泳動
• キャピラリーゲル電気泳動
• 世界のファーマコゲノミクス市場質量分析のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• LC-MS/MS（液体クロマトグラフィー-タンデム質量分析法）
• MALDI-TOF MS（マトリックス支援レーザー脱離/イオン化飛行時間法）
• HRMS（高分解能質量分析）
• 世界のファーマコゲノミクス市場、マイクロアレイのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• SNPマイクロアレイ
• 発現マイクロアレイ
• 比較ゲノムハイブリダイゼーション（CGH）アレイ
• 世界のファーマコゲノミクス市場、その他のテクノロジーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• サンガーシーケンス
• CRISPRベースの技術
• バイオインフォマティクスツール

第7章 地域別・国別分析

• 世界のファーマコゲノミクス市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のファーマコゲノミクス市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ファーマコゲノミクス市場：競合情勢
• ファーマコゲノミクス市場：企業プロファイル
  • Illumina Inc Overview, Products and Services, Strategy and Financial Analysis
  • Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis
  • Myriad Genetics Inc Overview, Products and Services, Strategy and Financial Analysis
  • PerkinElmer Inc Overview, Products and Services, Strategy and Financial Analysis
  • Centogene N.V Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Invitae Corporation
• Genomind
• Pacific Biosciences of California Inc
• Oneome LLC
• Admera Health
• MapMyGenome
• Positive Bioscience
• Xcode Life Sciences
• Xcelris Labs
• Takeda Pharmaceutical Company Limited
• Garvan Institute of Medical Research
• 3D Medicines Inc
• Berry Genomics
• BGI
• GenomiCare Biotechnology

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ファーマコゲノミクス市場2029：新たな機会を提供する国
• ファーマコゲノミクス市場2029：新たな機会を提供するセグメント
• ファーマコゲノミクス市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pharmacogenomics is a research field that explores how a patient's genes influence their response to medications. Its ultimate goal is to assist doctors in selecting the most appropriate drugs and doses tailored to each individual. Pharmacogenomics is instrumental in developing personalized drugs to address various health conditions, including cardiovascular disease, Alzheimer's disease, cancer, and asthma. The term 'pharmacogenomics marker' refers to a precise medical treatment approach for individuals or specific groups.

Key technologies employed in the pharmacogenomics market include next-generation sequencing (NGS), polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others. NGS, a massively parallel sequencing technology, offers ultra-high throughput, scalability, and speed, enabling the determination of nucleotide order in entire genomes or specific DNA/RNA regions. Pharmacogenomics applications span neurological diseases, infectious diseases, oncology, cardiovascular diseases, pain management, and various other areas. End-users encompass hospitals and clinics, research institutions, academic institutes, and others.

The pharmacogenomics market research report is one of a series of new reports from The Business Research Company that provides pharmacogenomics market statistics, including pharmacogenomics industry global market size, regional shares, competitors with a pharmacogenomics market share, detailed pharmacogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenomics industry. This pharmacogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharmacogenomics market size has grown rapidly in recent years. It will grow from $8.94 billion in 2024 to $9.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to strong economic growth in emerging markets, the increasing focus on personalized medicine, the rising advanced healthcare infrastructure and increased healthcare expenditure.

The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $14.81 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to the increasing aging population, the increasing chronic diseases, the rising population and the increasing demand for cancer treatment. Major trends in the forecast period include launch of genome editing solution for deeper analysis of advanced therapies, focus on integration of artificial intelligence (AI) in genomics to analyze genetic data, growing advancements in metagenomics, strategic partnerships and collaborations among market players, introduction of three-dimensional (3D) genomics to study influences on gene expression and function, new product innovations with focus on infectious diseases and gene editing and development of psychotropic pharmacogenomics test for informed decisions.

The growing demand for precision medicine is fueling the expansion of the pharmacogenomics market. Precision medicine, a healthcare model focused on personalized treatment tailored to specific patient subsets, is gaining traction, especially in advanced areas such as oncology. Its applications extend beyond late-stage diseases to encompass rare and genetic conditions. Precision medicine aims to integrate genetic and environmental information to tailor treatments for specific diseases and responses. A Linchpinseo article from March 2022 indicates a 1/3 increase in precision medicine investment by leading pharmaceutical companies over the next five years. In the USA, where 30 million people with type 2 diabetes are diagnosed and treated, precision medicine offers individualized treatment, reshaping current practices. The rising demand for precision medicine is a key driver propelling the pharmacogenomics market.

The pharmacogenomics market is expected to experience growth due to the increasing prevalence of chronic diseases. Chronic diseases, persistent over an extended period, pose a significant global health challenge. Pharmacogenomics provides a personalized treatment approach, considering individual genetic variations influencing drug responses. According to the World Health Organization's September 2023 report, non-communicable diseases (NCDs) or chronic diseases account for 74% of the 41 million annual deaths worldwide. Cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The upward trend in chronic diseases is a major factor propelling the pharmacogenomics market.

Technological advancement is becoming a prominent trend in the pharmacogenomics market. Pharmaceutical manufacturers are exploring various methods for pharmacogenomics analysis to deliver cost-effective solutions for screening known polymorphisms and discovering novel variants. For example, in May 2022, Invitae, a US-based medical laboratory organization, launched its expanded Pharmacogenomics Panel. This panel, which includes the Mental Health Panel, offers insights into genetic responses to medications across several specialties, such as primary care, cardiology, and oncology. With nearly 25% of patients experiencing atypical drug responses due to genetic factors, pharmacogenomics (PGx) testing is poised to become a standard practice. To ensure effective integration into healthcare, there is a need for enhanced support to help providers understand and apply PGx testing within their clinical environments.

Companies in the pharmacogenomics market are concentrating on the development of innovative solutions for infectious disease diagnosis and gene editing to fortify their market standing. For instance, in March 2022, Thermo Fisher Scientific Inc., a U.S.-based supplier of analytical instruments and life sciences solutions, introduced the latest generation of its SeqStudio Flex Series Genetic Analyzer. This innovative tool, leveraging Capillary Electrophoresis (CE) technology, enhances research in infectious disease diagnosis and gene editing. The SeqStudio Flex Genetic Analyzer, available in 8- and 24-capillary configurations, delivers high-quality data and reliable performance across various applications.

In June 2023, Genomenon, a U.S.-based genomics intelligence company, acquired Boston Genetics for an undisclosed amount. This strategic acquisition combines Genomenon's AI-powered genomic platform with Boston Genetics' genetic scientists to comprehensively curate the human genome. The acquisition strengthens clinical diagnostic and pharmaceutical drug development programs by providing valuable insights into the genomic drivers of genetic diseases and oncology. Additionally, it establishes a genomics data service arm for Genomenon, offering cost-effective variant curation team extensions for genetic testing labs, expediting turnaround times. Boston Genetics, a genomics interpretation and curation company based in the U.S., is part of this acquisition.

Major companies operating in the pharmacogenomics market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Laboratorio Richet, Laboratorio Exame, Genomika Diagnosticos

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharmacogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The pharmacogenomics market includes revenues earned by entities by PennCNV,QuantiSNP, GenoCN and Nexus.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmacogenomics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmacogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharmacogenomics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmacogenomics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies
• 2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications
• 3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users
• Subsegments:
• 1) By Next Generation Sequencing (NGS): Whole Genome Sequencing; Targeted Sequencing; Exome Sequencing
• 2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR); Reverse Transcription PCR (RT-PCR); Digital PCR
• 3) By Gel Electrophoresis: Agarose Gel Electrophoresis; Polyacrylamide Gel Electrophoresis; Capillary Gel Electrophoresis
• 4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry); MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight); HRMS (High-Resolution Mass Spectrometry)
• 5) By Microarray: SNP Microarrays; Expression Microarrays; Comparative Genomic Hybridization (CGH) Arrays
• 6) By Other Technologies: Sanger Sequencing; CRISPR-Based Technologies; Bioinformatics Tools
• Companies Mentioned: Illumina Inc; Eurofins Scientific; Myriad Genetics Inc; PerkinElmer Inc; Centogene N.V
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pharmacogenomics Market Characteristics

3. Pharmacogenomics Market Trends And Strategies

4. Pharmacogenomics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pharmacogenomics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pharmacogenomics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pharmacogenomics Market Growth Rate Analysis
• 5.4. Global Pharmacogenomics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pharmacogenomics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pharmacogenomics Total Addressable Market (TAM)

6. Pharmacogenomics Market Segmentation

• 6.1. Global Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next Generation Sequencing
• Polymerase Chain Reaction
• Gel Electrophoresis
• Mass Spectrometry
• Microarray
• Other Technologies
• 6.2. Global Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurological Diseases
• Infectious Diseases
• Oncology
• Cardiovascular Diseases
• Pain Management
• Other Applications
• 6.3. Global Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals and Clinics
• Research Institutions
• Academic Institutes
• Other End Users
• 6.4. Global Pharmacogenomics Market, Sub-Segmentation Of Next Generation Sequencing (NGS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole Genome Sequencing
• Targeted Sequencing
• Exome Sequencing
• 6.5. Global Pharmacogenomics Market, Sub-Segmentation Of Polymerase Chain Reaction (PCR), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Quantitative PCR (qPCR)
• Reverse Transcription PCR (RT-PCR)
• Digital PCR
• 6.6. Global Pharmacogenomics Market, Sub-Segmentation Of Gel Electrophoresis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Agarose Gel Electrophoresis
• Polyacrylamide Gel Electrophoresis
• Capillary Gel Electrophoresis
• 6.7. Global Pharmacogenomics Market, Sub-Segmentation Of Mass Spectrometry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry)
• MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight)
• HRMS (High-Resolution Mass Spectrometry)
• 6.8. Global Pharmacogenomics Market, Sub-Segmentation Of Microarray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SNP Microarrays
• Expression Microarrays
• Comparative Genomic Hybridization (CGH) Arrays
• 6.9. Global Pharmacogenomics Market, Sub-Segmentation Of Other Technologies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sanger Sequencing
• CRISPR-Based Technologies
• Bioinformatics Tools

7. Pharmacogenomics Market Regional And Country Analysis

• 7.1. Global Pharmacogenomics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pharmacogenomics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pharmacogenomics Market

• 8.1. Asia-Pacific Pharmacogenomics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pharmacogenomics Market

• 9.1. China Pharmacogenomics Market Overview
• 9.2. China Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pharmacogenomics Market

• 10.1. India Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pharmacogenomics Market

• 11.1. Japan Pharmacogenomics Market Overview
• 11.2. Japan Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pharmacogenomics Market

• 12.1. Australia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pharmacogenomics Market

• 13.1. Indonesia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pharmacogenomics Market

• 14.1. South Korea Pharmacogenomics Market Overview
• 14.2. South Korea Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pharmacogenomics Market

• 15.1. Western Europe Pharmacogenomics Market Overview
• 15.2. Western Europe Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pharmacogenomics Market

• 16.1. UK Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pharmacogenomics Market

• 17.1. Germany Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pharmacogenomics Market

• 18.1. France Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pharmacogenomics Market

• 19.1. Italy Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pharmacogenomics Market

• 20.1. Spain Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pharmacogenomics Market

• 21.1. Eastern Europe Pharmacogenomics Market Overview
• 21.2. Eastern Europe Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pharmacogenomics Market

• 22.1. Russia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pharmacogenomics Market

• 23.1. North America Pharmacogenomics Market Overview
• 23.2. North America Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pharmacogenomics Market

• 24.1. USA Pharmacogenomics Market Overview
• 24.2. USA Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pharmacogenomics Market

• 25.1. Canada Pharmacogenomics Market Overview
• 25.2. Canada Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pharmacogenomics Market

• 26.1. South America Pharmacogenomics Market Overview
• 26.2. South America Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pharmacogenomics Market

• 27.1. Brazil Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pharmacogenomics Market

• 28.1. Middle East Pharmacogenomics Market Overview
• 28.2. Middle East Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pharmacogenomics Market

• 29.1. Africa Pharmacogenomics Market Overview
• 29.2. Africa Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pharmacogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pharmacogenomics Market Competitive Landscape And Company Profiles

• 30.1. Pharmacogenomics Market Competitive Landscape
• 30.2. Pharmacogenomics Market Company Profiles
  • 30.2.1. Illumina Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Myriad Genetics Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. PerkinElmer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Centogene N.V Overview, Products and Services, Strategy and Financial Analysis

31. Pharmacogenomics Market Other Major And Innovative Companies

• 31.1. Invitae Corporation
• 31.2. Genomind
• 31.3. Pacific Biosciences of California Inc
• 31.4. Oneome LLC
• 31.5. Admera Health
• 31.6. MapMyGenome
• 31.7. Positive Bioscience
• 31.8. Xcode Life Sciences
• 31.9. Xcelris Labs
• 31.10. Takeda Pharmaceutical Company Limited
• 31.11. Garvan Institute of Medical Research
• 31.12. 3D Medicines Inc
• 31.13. Berry Genomics
• 31.14. BGI
• 31.15. GenomiCare Biotechnology

32. Global Pharmacogenomics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmacogenomics Market

34. Recent Developments In The Pharmacogenomics Market

35. Pharmacogenomics Market High Potential Countries, Segments and Strategies

• 35.1 Pharmacogenomics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pharmacogenomics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pharmacogenomics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer